Rosacea

Research into the microbiome of the skin is advancing. A greater understanding of how the different microbes interact may lead to new treatment options for conditions like rosacea, but more questions still remain.

A recent study has shed some light on the genetic predisposition of rosacea as well as other associated environmental factors, which could lead to improved treatment and management of the disease.

Nearly half of rosacea patients thought they had acne before being diagnosed. Learn how to explain the difference between rosacea and acne to patients and help them get the care they need.

Researchers assess the impact of facial erythema on the subconscious perceptions and initial reactions of others and how these affect their resulting attitudes.

Researchers have identified gene variants that could lead to new treatment targets and a better understanding of rosacea.

Emerging therapies for rosacea have a favorable side effect profile and address specific symptoms of the condition; brimonidine, for example, addresses background erythema while ivermectin addresses the papules and pustules.

Treating common skin conditions such as rosacea and melasma with appropriate topical agents, chemical peels, devices and cosmeceuticals can build trust among patients who may require additional dermatological services, experts say.

Lead author and a Galderma consultant dermatologist Linda Stein Gold, M.D. writes to Dermatology Times that results from Soolantra (ivermectin) Cream, 1% were seen in clinical studies as early as week two, with continuous improvement in patients with inflammatory lesions of rosacea.

Topical ivermectin cream 1 percent has shown safety and statistically superior efficacy versus vehicle as early as week two of treatment in phase 3 trials.

As researchers learn more about the pathogenesis of rosacea, they can better understand the benefits of certain medications and find opportunities for new therapies.

In the search for rosacea treatments, topical ivermectin 1 percent cream met its safety endpoints in two pivotal trials that included a total of 910 actively treated subjects, Galderma announced at the 72nd Annual Meeting of the American Academy of Dermatology.

A study shows data to suggest there is evidence of subtype progression in rosacea, and that flushing is not a universal characteristic of patients with subtype 1 rosacea.

Although the symptoms of acne and rosacea are well established, clear and definitive etiologies of these conditions have largely been unknown. Recent research, however, has shed new light into the pathophysiology of these conditions, paving the way for more targeted therapies.

Women who suffer from migraines may have a slightly higher risk of rosacea, a study suggests.

The treatment of rosacea is becoming increasingly patient-friendly, according to an expert.